These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16264350)

  • 1. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
    Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
    Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
    Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
    J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
    Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
    Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraindividual comparison of 99mTc-labelled anti-SSEA-1 antigranulocyte antibody and 99mTc-HMPAO labelled white blood cells for the imaging of infection.
    Gratz S; Behr T; Herrmann A; Dresing K; Tarditi L; Franceschini R; Rhodes B; Stürmer KM; Becker W
    Eur J Nucl Med; 1998 Apr; 25(4):386-93. PubMed ID: 9553168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.
    Vallis KA; Reilly RM; Chen P; Oza A; Hendler A; Cameron R; Hershkop M; Iznaga-Escobar N; Ramos-Suzarte M; Keane P
    Nucl Med Commun; 2002 Dec; 23(12):1155-64. PubMed ID: 12464779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
    Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
    Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
    Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
    Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
    Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
    J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
    Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
    Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
    Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
    J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
    Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
    Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.